These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28218257)

  • 1. Approvals in 2016: cost-benefit challenges of new anticancer agents.
    Savage P
    Nat Rev Clin Oncol; 2017 Feb; 14(3):133-134. PubMed ID: 28218257
    [No Abstract]   [Full Text] [Related]  

  • 2. Drug treatment for melanoma: progress, but who pays?
    Kefford RF
    Med J Aust; 2012 Aug; 197(4):198-9. PubMed ID: 22900855
    [No Abstract]   [Full Text] [Related]  

  • 3. Venetoclax (Venclexta) for chronic lymphocytic leukemia.
    Med Lett Drugs Ther; 2016 Aug; 58(1500):101-2. PubMed ID: 27466751
    [No Abstract]   [Full Text] [Related]  

  • 4. Approvals in 2016: questioning the clinical benefit of anticancer therapies.
    Booth CM; Del Paggio JC
    Nat Rev Clin Oncol; 2017 Feb; 14(3):135-136. PubMed ID: 28218259
    [No Abstract]   [Full Text] [Related]  

  • 5. [Patients with cancer denied treatment with new expensive drugs].
    Linné T
    Lakartidningen; 2012 Jun 27-Jul 17; 109(26-28):1298. PubMed ID: 22852261
    [No Abstract]   [Full Text] [Related]  

  • 6. New Drugs 2017, part 3.
    Hussar DA
    Nursing; 2017 Nov; 47(11):26-32. PubMed ID: 28991071
    [No Abstract]   [Full Text] [Related]  

  • 7. NICE recommends kidney cancer drug it previously rejected on cost grounds.
    Mayor S
    BMJ; 2009 Feb; 338():b499. PubMed ID: 19204038
    [No Abstract]   [Full Text] [Related]  

  • 8. Pioneering apoptosis-targeted cancer drug poised for FDA approval.
    Mullard A
    Nat Rev Drug Discov; 2016 Mar; 15(3):147-9. PubMed ID: 26931080
    [No Abstract]   [Full Text] [Related]  

  • 9. Watchdog set to reject four drugs for kidney cancer on the NHS.
    O'Dowd A
    BMJ; 2008 Aug; 337():a1262. PubMed ID: 18703648
    [No Abstract]   [Full Text] [Related]  

  • 10. New Math on Drug Cost-Effectiveness.
    Bach PB
    N Engl J Med; 2015 Nov; 373(19):1797-9. PubMed ID: 26535510
    [No Abstract]   [Full Text] [Related]  

  • 11. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [European approvals: Glasdegib for Acute myeloid leukemia].
    Barrière S; Gastaud L
    Bull Cancer; 2020 Dec; 107(12):1206-1207. PubMed ID: 33070952
    [No Abstract]   [Full Text] [Related]  

  • 13. A BH3 Mimetic for Killing Cancer Cells.
    Green DR
    Cell; 2016 Jun; 165(7):1560. PubMed ID: 27315468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How much will Herceptin really cost?
    Barrett A; Roques T; Small M; Smith RD
    BMJ; 2006 Nov; 333(7578):1118-20. PubMed ID: 17124225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Roche responds to the 'Herceptin or deception' article.
    Petersen S
    N Z Med J; 2006 Jul; 119(1237):U2069; author reply U2069. PubMed ID: 16862210
    [No Abstract]   [Full Text] [Related]  

  • 16. Drug treatment for melanoma: progress, but who pays?
    Fullerton S
    Med J Aust; 2012 Nov; 197(9):491. PubMed ID: 23121579
    [No Abstract]   [Full Text] [Related]  

  • 17. Drug treatment for melanoma: progress, but who pays?
    Morgan GW
    Med J Aust; 2012 Nov; 197(9):491. PubMed ID: 23121578
    [No Abstract]   [Full Text] [Related]  

  • 18. Response to "A financial perspective on the topical treatment of onychomycosis".
    Elewski BE
    J Am Acad Dermatol; 2016 Jul; 75(1):e39. PubMed ID: 27317545
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug treatment for melanoma: progress, but who pays? Comment.
    Kefford RF
    Med J Aust; 2012 Nov; 197(9):492. PubMed ID: 23121580
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.